Treatment of Kasabach-Merritt syndrome: A stepwise regimen of prednisolone, dipyridamole, and interferon

International Journal of Dermatology

Volumn 42, Issue 9, 2003, Pages 741-748

  Wananukul, Siriwan ^a   Nuchprayoon, Issaraang ^a   Seksarn, Panya ^a  

^a CHULALONGKORN UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; CEFTAZIDIME; CLOXACILLIN; CORTICOSTEROID; DIPYRIDAMOLE; PREDNISOLONE; RECOMBINANT ALPHA2B INTERFERON; VINBLASTINE; VINCRISTINE;

ARTIFICIAL EMBOLISM; ASPIRATION PNEUMONIA; CANCER ADJUVANT THERAPY; CARPAL TUNNEL SYNDROME; CHILD; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONFERENCE PAPER; CUSHINGOID SYNDROME; DEATH; DIARRHEA; DRUG DOSE REGIMEN; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; HYPERTENSION; INFANT; KASABACH MERRITT SYNDROME; LEUKOPENIA; MALE; MONOTHERAPY; MULTIMODALITY CANCER THERAPY; PNEUMONIA; RESPIRATORY DISTRESS SYNDROME; RESPIRATORY FAILURE; SEPSIS; SEPTICEMIA; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THRUSH; TREATMENT FAILURE; TUMOR REGRESSION; URINARY TRACT INFECTION;

ABNORMALITIES, MULTIPLE; CHILD; COMBINED MODALITY THERAPY; DIPYRIDAMOLE; DRUG ADMINISTRATION SCHEDULE; EMBOLIZATION, THERAPEUTIC; FEMALE; HEMANGIOMA; HUMANS; INFANT; INTERFERON ALFA-2B; MAGNETIC RESONANCE IMAGING; MALE; MEDICAL RECORDS; PLATELET COUNT; PREDNISOLONE; RETROSPECTIVE STUDIES; SYNDROME; THAILAND; TREATMENT OUTCOME;

EID: 0141593627     PISSN: 00119059     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-4362.2003.01796.x     Document Type: Conference Paper

References (25)

1. Enjolras O, Wassef M, Mazoyer E, et al. Infants with Kasabach-Merritt syndrome do not have "true" hemangiomas. J Pediatr 1999; 130: 631-640.
2. Kasabach HH, Merritt KK. Capillary hemangioma with extensive purpura: Report of a case. Am J Dis Child 1940; 59: 1063-1070.
3. Sarkar M, Mulliken JB, Kazakewich HPW, et al. Thrombocytopenic coagulopathy (Kasabach-Merritt Phenomenon) is associated with kaposiform hemangioendothelioma and not with common infantile hemangioma. Plast Reconstr Surg 1997; 100: 1377-1386.
4. Hall GW. Kasabach-Merritt syndrome: Pathogenesis and management. Br J Haematol 2001; 118: 851-862.
5. Bearbien ER, Ball NJ, Storwick GS. Kaposiform hemangioendothelioma: A locally aggressive vascular tumor. J Am Acad Dermatol 1998; 38: 799-782.
6. Larsen EC, Zinkham WH, Egglestan JC, Zitelli BJ. Kasabach-Merritt syndrome: Therapeutic considerations. Pediatrics 1987; 79: 971-980.
7. Enjolras O, Mulliken JB, Wassef M, et al. Residual lesions after Kasabach-Merritt Phenomenon in 41 patients. J Am Acad Dermatol 2000; 42: 225-235.
8. Zukeberg LR, Nickoloff BJ, Weiss SW. Kaposiform hemangioendothelioma of infancy and childhood: An aggressive neoplasm associated with Kasabach-Merritt syndrome and lymphangiomatosis. Am J Surg Pathol 1993; 17: 321-328.
9. Fukunaga M, Ushigome S, Ishikawa E. Kaposiform hemangioendothelioma associated with Kasabach-Merritt syndrome. Histopathology 1996; 28: 281-284.
10. Alvarez-Mendoza A, Lourdes TS, Ridaura-Sanz C, Ruiz-Maldonado K. Histopathology of vascular lesions found in Kasabach-Merritt syndrome: Review based on 13 cases. Pediatr Dev Pathol 2000; 3: 556-560.
11. Neubert AG, Golden MA, Pose NC, Kasabach-Merritt coagulopathy complicating Klippel-Trenaunay-Weber syndrome in pregnancy. Am Coll Obstetr Gynecol 1995; 85: 831-833.
12. Singh G, Rajendrom C. Kasabach-Merritt syndrome in two successive pregnancies. Int J Dermatol 1998; 37: 687-700.
13. Shoji N, Nakada T, Sugano O, et al. Acute onset of coagulopathy in a patient with Kasabach-Merritt syndrome following transurethral resection of bladder tumor. Urol Int 1998; 61: 115-118.
14. Phillips WG, Marsden JR. Kasabach-Merritt syndrome exacerbated by platelet transfusion. J R Soc Med 1993; 86: 231-232.
15. Seo SK, Suh JC, Na GY, et al. Kasabach-Merritt syndrome: Identification of platelet trapping in a tufted angioma by immunohistochemistry technique using monoclonal antibody to CD61. Pediatr Dermatol 1999; 16: 392-394.
16. Shin HY, Ryu KH, Ahn HS. Stepwise multimodal approach in the treatment of Kasabach-Merritt syndrome. Pediatrics Int 2000; 42: 620-624.
17. Mitsuhashi N, Furuta M, Sakurai H, et al. Outcome of radiation therapy for patients with Kasabach-Merritt syndrome. Int J Radiat Oncol Biol Phys 1997; 39: 467-473.
18. Boon LM, MacDonald DM, Mulliken JB. Complications of systemic corticosteroid therapy for problematic hemangioma. Plast Reconstr Surg 1999; 104: 1616-1623.
19. Ezekowitz RAB, Mulliken JB, Folkman J. Interferon alfa-2a therapy for life-threatening hemangioma of infancy. N Engl J Med 1992; 326: 1456-1463.
20. Barlow CF, Priebe CJ, Mulliken JB, et al. Spastic diplegia as a complication of interferon alfa-2a treatment of hemangiomas of infancy. J Pediatr 1998; 132: 527-530.
21. Dubois J, Hershon L, Carmant L, et al. Toxicity profile of interferon alfa-2b in children: A prospective evaluation. J Pediatr 1998; 135: 782-785.
22. Schirner M, Hoffman J, Menrad A, Schneider MR. Antiangiogenic chemotherapeutic agents: Characterization in comparison to their tumor growth inhibition in human renal cell carcinoma models. Clin Cancer Res 1998; 4: 1331-1336.
23. Vacca A, Lurlaro M, Ribatti D, et al. Antiangiogenesis is reduced by nontoxic doses of vinblastine. Blood 1999; 15: 4143-4155.
24. Moore J, Lee M, Garzon M, et al. Effective therapy of a vascular tumor of infancy with vincristine. J Pediatr Surg 2001; 36: 1273-1276.
25. Drolet BA, Scott LA, Esterly NB, Gosain AK. Early surgical intervention in a patient with Kasabach-Merritt phenomenon. J Pediatr 2001; 138: 756-758.